Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014:2014:689308.
doi: 10.1155/2014/689308. Epub 2014 May 12.

Implementation study of patient-ready syringes containing 25 mg/mL methotrexate solution for use in treating ectopic pregnancy

R Respaud  1 , A S Gaudy  2 , C Arlicot  3 , J F Tournamille  1 , M C Viaud-Massuard  4 , C Elfakir  5 , D Antier  2
Affiliations

Implementation study of patient-ready syringes containing 25 mg/mL methotrexate solution for use in treating ectopic pregnancy

R Respaud et al. Biomed Res Int. 2014.

Abstract

Background: Ectopic pregnancy (EP) is a significant cause of morbidity and mortality during the first trimester of pregnancy. Small unruptured tubal pregnancies can be treated medically with a single dose of methotrexate (MTX).

Objective: The aim of this study was to evaluate the stability of a 25 mg/mL solution of MTX to devise a secure delivery circuit for the preparation and use of this medication in the management of EP.

Method: MTX solutions were packaged in polypropylene syringes, stored over an 84-day period, and protected from light either at +2 to +8°C or at 23°C. We assessed the physical and chemical stability of the solutions at various time points over the storage period. A pharmaceutical delivery circuit was implemented that involved the batch preparation of MTX syringes.

Results: We show that 25 mg/mL MTX solutions remain stable over an 84-day period under the storage conditions tested. Standard doses were prepared, ranging from 50 mg to 100 mg. The results of this study suggest that MTX syringes can be prepared in advance by the pharmacy, ready to be dispensed at any time that a diagnosis of EP is made.

Conclusion: The high stability of a 25 mg/mL MTX solution in polypropylene syringes makes it possible to implement a flexible and cost-effective delivery circuit for ready-to-use preparations of this drug, providing 24-hour access and preventing treatment delays.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pharmaceutical dispensing circuit.
See this image and copyright information in PMC

References

    1. Farquhar CM. Ectopic pregnancy. The Lancet. 2005;366(9485):583–591. - PubMed
    1. Fernandez H, Capmas P, Lucot JP, Resch B, Panel P, Bouyer J. GROG. Fertility after ectopic pregnancy: the DEMETER randomized trial. Human Reproduction. 2013;28(5):1247–1253. - PubMed
    1. Skubisz MM, Tong S. The evolution of methotrexate as a treatment for ectopic pregnancy and gestational trophoblastic neoplasia: a review. ISRN Obstetrics and Gynecology. 2012;2012637094 - PMC - PubMed
    1. Tanaka T, Hayashi H, Kutsuzawa T, Fujimoto S, Ichinoe K. Treatment of interstitial ectopic pregnancy with methotrexate: report of a successful case. Fertility and Sterility. 1982;37(6):851–852. - PubMed
    1. Dhar H, Hamdi I, Rathi B. Methotrexate treatment of ectopic pregnancy: experience at Nizwa hospital with literature review. Oman Medical Journal. 2011;26(2):94–98. - PMC - PubMed